silence is golden ??, page-28

Hello xxxx



Thankyou for your email.



In the case you have stated, it is quite common for 3M to be paid to evaluate the pharmacokinetics of any drug in a 3M patch adhesive system. This may be sufficiently promising for a Phase 1 clinical trial to take place. This process is not normally commercially sensitive. 3M is primarily a contract manufacturer so works with many different drug companies to further those companies’ compounds.



OBJ works with quite a different model. OBJ works with major international pharmaceutical and FMCG companies to help them develop new products. This is highly secretive work as these are highly competitive sectors, so our partners rarely permit us to announce our progress, as that would alert competitors to where these majors are focusing their product development plans.



I hope that helps to explain the differences.



Thankyou again for your question xxxx



Kind Regards,



Glyn Denison,

OBJ Ltd.





From: xxxx
Sent: Friday, 12 October 2012 3:44 AM
To: Glyn Denison
Subject:



To Glyn

As a investor of Obj Limited it amazes me with market announcements that all technologies that Obj claim to be advancing that there is no time lines for each product or what stage they are at?
If you kindly cut and and paste this link http://www.in-pharmatechnologist.com/Drug-Delivery/3M-patch-tech-under-assessment-for-osteoporosis-drug-delivey you will see Radius and 3M are stating what the product does and what stage the product is at. Would it be possible to include in future announcements these time lines or even product progress?

Thankyou once again